TY - JOUR T1 - Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia JF - Saudi Medical Journal JO - Saudi Med J SP - 697 LP - 704 DO - 10.15537/smj.2018.7.22146 VL - 39 IS - 7 AU - Saud Al Sifri AU - Owayed Al Shammeri AU - Saleh Al Jaser AU - Abdullah Alkhenizan AU - Atif Bin Shafi Shafiurrehman AU - Bassem Morcos AU - Sameh Wajih AU - Ibrahim Elnahal AU - Martin Horack AU - Philippe Brudi AU - Dominik Lautsch AU - Baishali Ambegaonkar AU - Ami Vyas AU - Carl A. Baxter AU - Anselm K. Gitt Y1 - 2018/07/01 UR - http://smj.org.sa/content/39/7/697.abstract N2 - Objectives: To provide an overview of the extent of hyperlipidemia in very high-risk patients, and how lipid-lowering therapy (LLT) is used in a real-world setting.Methods: In this multicenter observational study, data were collected from LLT-treated patients with stable CHD or an ACS in Saudi Arabia between 2013 and 2014. Individuals were included if they were >18 years and had a full lipid profile available, recorded either prior to the baseline physician visit (CHD patients) or within 24-hours of admission to hospital (ACS patients).Results: A total of 737 patients were included in the study, 597 with stable CHD and 140 with ACS. Few patients in either group had an LDL-C level of <70 mg/dl, which is advocated for very high-risk patients (24.3% and 11.4%, respectively). The median distances to this value were 19.0 mg/dl (CHD) and 25.0 mg/dl (ACS). Low doses of statins were being utilized (31 and 24 mg/day for CHD and ACS, respectively), with only minimal intensification for the ACS patients after hospital admission (41 mg/day at follow-up).Conclusions: Achievement of recommended LDL-C levels was poor for patients with stable CHD or an ACS. Statin intensity was low, indicating huge scope for intensifying the treatment of these very high-risk patients. ER -